Urine Tenofovir Levels Strongly Correlate With Virologic Suppression in Patients With Human Immunodeficiency Virus on Tenofovir Alafenamide-Based Antiretroviral Therapy

Clin Infect Dis. 2023 Mar 4;76(5):930-933. doi: 10.1093/cid/ciac828.

Abstract

We found that urine tenofovir (TFV) levels >1500 ng/mL strongly predict virologic suppression among people with human immunodeficiency virus taking tenofovir alafenamide (odds ratio, 5.66; 95% confidence interval, 1.59-20.14; P = .007). This suggests an existing point-of-care assay developed for tenofovir disoproxil fumarate will support adherence monitoring for patients on all TFV-based antiretrovirals.

Keywords: adherence; point-of-care monitoring; tenofovir alafenamide; viral suppression.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenine / therapeutic use
  • Alanine / therapeutic use
  • Anti-HIV Agents* / therapeutic use
  • HIV Infections* / drug therapy
  • HIV-1*
  • Humans
  • Tenofovir / therapeutic use

Substances

  • Tenofovir
  • Anti-HIV Agents
  • Alanine
  • Adenine